Herantis Pharma Oyj
HRPMF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$70.77M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $70.77 Million |
|---|---|
| Enterprise Value | $73.47 Million |
| Earnings per Share | $-0.24 |
| Beta | 0.43 |
| Outstanding Shares | 20,161,000 |
Return
| Return on Equity | 1532.29% |
|---|---|
| Return on Assets | -302.06% |
| Return on Invested Capital | -443.26% |
Valuation & Multiples
| P/E Ratio | -4.37 |
|---|---|
| PEG | -113.74 |
| Price to Sales | - |
| Price to Book Ratio | -3.51 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -6.27 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | -4.33 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Herantis Pharma Oyj
14 employees
CEO: Antti Vuolanto
Herantis Pharma Oyj, a biotechnology company founded in Espoo, Finland, in 2008, is dedicated to developing innovative, disease-modifying CDNF-based treatments for Parkinson's disease (PD). Its pipeline features two key assets: HER-096, ...